智通财经APP讯，中国卫生集团(00673)发布公告，于2026年2月2日，公司已根据公司于2023年9月18日 采纳的购股权计划向11名合资格参与者授出合共4063.8万份购股权，以认购最多合共4063.8万股公司每 股面值0.1港元的普通股，占于本公布日期公司已发行股本约3.03%，惟须待承授人接纳后，方可作实。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就本公佈全部或任何部分內容產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 China Health Group Limited 中國衛生集團有限公司 （以CHG HS Limited名稱在香港經營業務） （於百慕達註冊成立之有限公司） （股份代號：673） 授出購股權 | 授出購股權之代價 | ： | 各承授人於接納所授購股權時將予支付之1.00港元 | | --- | --- | --- | | 所授出購股權之行使期 | ： | 承授人可於授出日期起計10年屆滿前隨時行使根據下段 | | | | 所歸屬的購股權。 | | 所授出購股權之歸屬期 | ： | 所有已授出購股權應於授出日期之一週年當日（即二零 | | | | 二七年二月二日）歸屬。 | | 表現目標 | ： | 授出購股權並無附帶表現目標。鑒於(i)承授人為一直及 | | | | 將直接對本集團的整體業務表現及可持續發展作出貢獻 | | | | 的本集團董事或僱員；及(ii)授出乃對承授人過往對本集 | | | | ...

中國衛生集團有限公司（「本公司」）董事會謹此更新其解決核數師對本公司截至二零二五年三月 三十一日止年度綜合財務報表有關持續經營不發表意見（「不發表意見」）的行動。 茲提述本公司截至二零二五年三月三十一日止年度之年報（「年報」）及二零二五年十一月十九日 之公告（「該公告」）。除非文義另有所指，本公佈所用詞彙與年報內所界定者具有相同涵義。 誠如年報所載，為解決截至二零二六年三月三十一日止年度本集團之流動資金壓力及不發 表意見，董事會積極實施多項計劃及措施，包括(i)訂立認購協議以籌集估計所得款項總額約 70,000,000港元；(ii)建議供股以籌集估計所得款項總額約15,000,000港元；(iii)與銀行磋商續期 本集團於二零二五年三月三十一日的銀行借貸約5,400,000港元；及(iv)通過多種渠道尋求潛在的 新資金（如需要）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就本公佈全部或任何部分內容產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 China Health Group Limited 中國衛生集團有限公司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國衛生集團有限公司 ( 以 CHG HS Limited 名稱在香港經營業務) ( 於百慕達註冊成立之有限公司) 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00673 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 HKD | | 0.1 | HKD | | 10,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 100,000,000,000 HKD | ...

China Health Group Limited 中國衛生集團有限公司 (Carrying on business in Hong Kong as CHG HS Limited) (Incorporated in Bermuda with limited liability) （以 CHG HS Limited 名稱在香港經營業務） （於百慕達註冊成立之有限公司） （Stock Code 股份代號：673） NOTIFICATION LETTER 通知信函 Dear Non-Registered Shareholders, China Health Group Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's w ...

China Health Group Limited 中國衛生集團有限公司 (Carrying on business in Hong Kong as CHG HS Limited) (Incorporated in Bermuda with limited liability) （以 CHG HS Limited 名稱在香港經營業務） （於百慕達註冊成立之有限公司） （Stock Code 股份代號：673） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, China Health Group Limited (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's w ...

Financial Performance - Revenue for the six months ended September 30, 2025, was HKD 19,610,000, an increase of 4.96% compared to HKD 18,680,000 for the same period in 2024[6] - Gross profit decreased to HKD 1,847,000, down 7.33% from HKD 1,993,000 year-over-year[6] - The company reported a net loss of HKD 10,839,000 for the six months ended September 30, 2025, an improvement from a loss of HKD 17,624,000 in the previous year[6] - The total loss for the period was HKD 17,387,000, compared to a loss of HKD 3,885,000 in the previous year, indicating a significant increase in losses[12] - The company reported a pre-tax loss of HKD 10,889,000, compared to a pre-tax loss of HKD 17,607,000 in the previous year, showing an improvement in loss management[18] - The company reported a loss of HKD 10,363,000 for the six months ended September 30, 2025, compared to a loss of HKD 17,387,000 in 2024, indicating a reduction in losses by 40.3%[28] Cash Flow and Assets - Operating cash flow for the six months was HKD 2,397,000, a significant recovery from a cash outflow of HKD 11,538,000 in the same period last year[11] - Total current assets increased to HKD 169,308,000 from HKD 114,620,000, reflecting a growth of 47.7%[8] - The company’s cash and bank balances at September 30, 2025, were HKD 63,021,000, a substantial increase from HKD 2,409,000 at the same time last year[11] - The total assets as of September 30, 2025, amounted to HKD 201,466,000, up from HKD 147,348,000 as of March 31, 2025, reflecting a growth of approximately 36.69%[20] - The total liabilities increased to HKD 211,969,000 from HKD 147,253,000, marking an increase of approximately 43.93%[20] Equity and Share Performance - The basic and diluted loss per share for the period was HKD 2.11, compared to HKD 3.59 in the previous year[7] - The total equity attributable to owners decreased to HKD 51,419,000 from HKD 59,753,000, indicating a decline of approximately 13.93%[12] - The company has issued 100,000,000 shares as of September 30, 2025, with paid-up capital amounting to HKD 49,164,000[42] - The company has a total of 1,339,138,191 shares issued[98] Segment Performance - The segment revenue from medical device distribution and services was HKD 15,551,000, compared to HKD 13,209,000 in the previous year, showing an increase of about 17.67%[18] - The segment performance for hospital management services reported a loss of HKD 3,264,000, slightly higher than the loss of HKD 3,218,000 in the previous year[18] Operational Developments - The company plans to launch new cardiovascular products, including pacemakers, by the second half of the fiscal year ending March 31, 2026[52] - The company has strategically adjusted its product portfolio to focus on higher-margin products and expand into new surgical fields, including tumor-related surgeries[52] - The company aims to leverage its existing strengths in cardiovascular product distribution while diversifying into new surgical areas[52] Legal and Compliance Matters - The company has a disputed dividend payable of USD 4,000,000 (approximately HKD 31,120,000) related to redeemable convertible cumulative preference shares[34] - The court ruled against Capital Foresight's claim for the USD 4,000,000 loan note, citing a lack of agreed maturity date as a defect[40] - The company is currently involved in ongoing litigation regarding the loan note, with an appeal hearing scheduled for August 27, 2024[41] Financing and Capital Raising - The company completed a rights issue on October 6, 2025, raising approximately HKD 80,900,000, intended for settling payables and general working capital[46] - The total amount raised from the rights issue and subscription was approximately HKD 84.7 million, with a net amount of approximately HKD 80.9 million[85] - The group plans to negotiate with banks for the renewal of existing loans by the end of Q1 2026[71] Employee and Governance - The total employee cost for the group was approximately HKD 8.2 million, compared to HKD 6.8 million in the previous period[90] - The group employed 127 employees as of September 30, 2025, down from 148 employees as of March 31, 2025[90] - The company has complied with the corporate governance code throughout the period, except for certain disclosures[105] Stock Options and Incentives - The company has granted stock options to 14 business consultants, including former directors and employees, to support business development and financial operations[101] - The stock options are expected to enhance employee retention and motivation, contributing to overall company performance[101]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國衛生集團有限公司 ( 以 CHG HS Limited 名稱在香港經營業務) ( 於百慕達註冊成立之有限公司) 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00673 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 HKD | | 0.1 | HKD | | 10,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 100,000,000,000 HKD ...

Group 1 - The core viewpoint of the article is that China Health Group (00673) reported its interim results for the six months ending September 30, 2025, showing a revenue of HKD 19.61 million, which represents a year-on-year increase of 4.98% [1] - The company reported a loss attributable to shareholders of HKD 10.36 million, which is a reduction of approximately 40.40% compared to the previous year [1] - The basic loss per share is HKD 0.0211 [1]

Financial Performance - Revenue for the six months ended September 30, 2025, was HKD 19,610,000, an increase of 4.96% compared to HKD 18,680,000 for the same period in 2024[4] - Gross profit decreased to HKD 1,847,000 from HKD 1,993,000, representing a decline of 7.33%[4] - The net loss for the period was HKD 10,839,000, an improvement from a net loss of HKD 17,624,000 in the previous year, indicating a reduction of 38.55%[5] - The total comprehensive loss for the period was HKD 10,648,000, compared to HKD 18,130,000 in the previous year, indicating a decrease of 41.06%[5] - The group reported a total loss of HKD 10,363,000 for the period, compared to a loss of HKD 17,387,000 in the previous period, indicating an improvement of approximately 40.5%[16] - The company reported a loss attributable to owners of HKD 10,363,000 in 2025, compared to a loss of HKD 17,387,000 in 2024, indicating a reduction in losses by 40.3%[30] Cash Flow and Assets - Operating cash flow improved significantly to HKD 2,397,000 from a cash outflow of HKD 11,538,000 in the prior period[9] - Financing activities generated a net cash inflow of HKD 59,682,000, compared to HKD 9,768,000 in the previous year, showing a substantial increase[9] - Total current assets increased to HKD 169,308,000 from HKD 114,620,000, reflecting a growth of 47.73%[6] - The total assets of the group as of September 30, 2025, amounted to HKD 201,466,000, an increase from HKD 147,348,000 as of March 31, 2025[18] - The total liabilities of the group as of September 30, 2025, were HKD 211,969,000, up from HKD 147,253,000 as of March 31, 2025[18] - The group's cash and cash equivalents amounted to approximately HKD 63 million, a significant increase from HKD 1 million as of March 31, 2025[91] Revenue Breakdown - The distribution of revenue from external customers in China was HKD 19,610,000 for the six months ended September 30, 2025, compared to HKD 18,680,000 in the previous year, reflecting a growth of approximately 4.95%[21] - Revenue from medical device and consumables distribution and services increased to HKD 15,551,000 in 2025 from HKD 13,209,000 in 2024, representing a growth of 17.7%[22] - Revenue from hospital operation and management services decreased to HKD 4,059,000 in 2025 from HKD 5,471,000 in 2024, a decline of 25.8%[22] - Total revenue for the period reached HKD 19,610,000 in 2025, up from HKD 18,680,000 in 2024, marking an increase of 4.9%[22] Liabilities and Provisions - Current liabilities rose to HKD 211,762,000 from HKD 131,965,000, an increase of 60.25%[6] - The company has recognized a provision of $4,000,000 (approximately HKD 31,120,000) in its profit and loss statement for the year ending March 31, 2025[45] - The company is actively pursuing repayment of outstanding loans, with a total of approximately RMB 59,100,000 (around HKD 64,800,000) in unpaid principal and interest from Shuangluan Hospital[66] Operational Developments - The company plans to launch new cardiovascular products, including pacemakers, in the second half of the fiscal year ending March 31, 2026[56] - The company has strategically adjusted its product portfolio to focus on high-margin products and expand into new surgical fields[56] - The hospital plans to shift its focus from capital-intensive surgical services to rehabilitation and nursing services, aiming to improve asset efficiency and align with national healthcare policies[60] - A new hospital director has been appointed to oversee the transition to a health management-centered model, with plans to hire more qualified medical personnel[64] Shareholder and Equity Matters - The company has issued 100,000,000 shares as of March 31, 2025, with paid-up capital of HKD 49,164,000[46] - The group’s total equity attributable to owners decreased to HKD 51,419,000 as of September 30, 2025, from HKD 59,753,000 as of April 1, 2024[10] - No interim dividend has been recommended for shareholders for the current period[96] Legal and Settlement Issues - The company has been involved in litigation regarding the $4,000,000 loan note, with the latest court ruling rejecting claims from Capital Foresight[44] - The court ruled that the statutory demand was an abuse of process and ordered the return of the $4,000,000 to the company[39] - The company entered into a settlement agreement involving the acquisition of Tsun Mei Group, which includes a payment of HKD 12,000,000[47] Employee and Management Changes - The total employee cost, including directors' remuneration, was approximately HKD 8.2 million, up from HKD 6.8 million in the previous period[94] - The group employed 127 employees as of September 30, 2025, down from 148 employees as of March 31, 2025[94] Future Outlook - The group aims to enhance its existing business and management team in the second half of the year, with expectations of improved operational performance compared to the previous year[95] - The company is in discussions with two leading cardiovascular hospitals in Beijing to introduce new cardiovascular products, expected to enhance revenue sources[57]